

The study of regioselectivity of ferrocenylalkylation of N,S- heterocycles in aqueous-organic media

Elena Yu. Rogatkina (Osipova)^a, Anna S. Ivanova^b, Alexey N. Rodionov^a, Alexander S. Peregudov^a, Alexander A. Korlyukov^a, Alexander D. Volodin^a, Yury A. Belousov,^a and Alexander A. Simenel^{*a,c}

^aA.N. Nesmeyanov Institute of OrganoElement Compounds, Russian Academy of Sciences, 28 Vavilov St., 119991 Moscow, Russian Federation

^bFederal State Budget Educational Institution of Higher Education «Moscow Technological University», 78 Vernadsky prospect, 119454 Moscow, Russian Federation

^cNational University of Science and Technology "MISIS", Chemistry Department, 4 Leninskiy prospekt, 119049 Moscow, Russian Federation

Email: alexsim@ineos.ac.ru


Received 11-27-2017

Accepted 05-06-2018

Published on line 07-03-2018

Abstract

Regioselectivity of ferrocenylalkylation reaction of mercaptoheterocycles with ferrocenylcarbinols in biphasic aqueous-organic media was studied. The structures of compounds were assigned on the basis of NMR spectra and ¹H/¹³C heteronuclear correlations. X-ray determination of molecular structures of 1-(ferrocenyl(phenyl)methyl)pyrrolidine-2-thione **5f**, 4,5-dihydro-1-(1-ferrocenylmethyl)-1H-imidazole-2-thiol **7a** and 4,5-dihydro-1-(1-ferrocenyl-2methylpropyl)-1H-imidazole-2-thiol **7e** were carried out.



R = H (a), CH₃(b), C₂H₅ (c), C₃H₇ (d), *i*-C₃H₇ (e), C₆H₅ (f)

X = S, NH, CH₂

Keywords: Ferrocene, ferrocenylalkylation, mercaptoheterocycles, regioselectivity, X-Ray analysis

Introduction

Ferrocene-containing heterocyclic compounds with great success have proved themselves as potential medicines for the treatment of diseases of various origin.¹⁻³ The presence of an antitumor effect in heterocyclic ferrocene derivatives is most relevant, because an effective and low-toxic anti-cancer drug has not yet been invented. Numerous *in vivo* and *in vitro* tests carried out by our group together with biologists have revealed a pronounced antitumor cytostatic effect of heterocyclic ferrocene derivatives.⁴⁻⁸ Moreover together with biologists from Lomonosov Moscow State University (Russian Federation) identified a sonodynamic effect (activity under the influence of ultrasound) of ferrocenylheterocyclic porphyrins was revealed in relation to the cells of *S. aureus* (*Staphylococcus aureus*).⁹


A convenient synthetic method for the production of heterocyclic ferrocene derivatives is the alkylation of azoles by hydroxy(alkyl)ferrocenes (FcCH(R)OH) (**1 a-e**) in a two-phase aqueous-organic system (water-methylene chloride) during the catalysis with a strong mineral acid with a non-oxidizing agent (HBF₄). Previously the alkylation of unsymmetrically substituted heterocycles with ferrocenylcarbinols was carried out. Our team reported recently that the reaction proceeded regioselectively if there was a significant difference in the electronic effects of the substituents on a heterocycle.¹⁰ However, the regioselectivity of the alkylation of ambident nucleophiles has not been adequately studied. This article is a continuation of our research in ferrocenylalkylation of sulfur-containing heterocyclic compounds¹¹ and dealing with a study of these reactions regioselectivity. Pyrrolidine-2-thione (**2**) 2-mercaptopythiazoline (**3**), and imidazolidin-2-thione (**4**) were chosen as ambident nucleophiles since they are pharmacophore groups and have a wide range of biological activity.¹²⁻¹⁴ The choice of heterocycles is not accidental, because they are part of many biologically active substances of natural origin and pharmaceuticals.¹⁵⁻¹⁹

Results and Discussion

The development of new efficient synthetic approaches towards ferrocene-containing heterocycles for the design of new biologically active compounds is still an ongoing challenge to organic chemists. Introduction of ferrocenylalkyl moiety into different structures can be achieved by ferrocenylalkylation; however, regioselectivity of this reaction is still poorly studied. Earlier we have described phase-transfer catalyzed alkylation of aromatic mercaptoheterocycles with ferrocenyl carbinols.²¹ It has been shown that the reaction is regioselective and proceeds on nitrogen atom of heterocycle. This was somewhat surprising, because sulfur is considered to be the best nucleophile relative to nitrogen, and in addition, alkylation at the nitrogen atom in 2-mercaptobenzoxazole and 2-mercaptobenzothiazole results in a loss of aromaticity in the reaction products. Furthermore, quantum chemical calculations show that *N*-isomers are more thermodynamically stable than the corresponding *S*-isomers.¹¹ Moreover, it was shown that under solvation conditions substitution at the nitrogen atom is always more favorable than substitution at the sulfur atom in aromatic heterocycles. This article is devoted to the study of ferrocenylalkylation regioselectivity of such non-aromatic heterocycles as pyrrolidin-2-thione, 2-mercaptopythiazoline and imidazolidin-2-thione under the conditions of phase-transfer catalysis.

Reactions of α -hydroxyalkylferrocenes with different nucleophilic compounds proceed most efficiently in two-component system, such as liquid-liquid. The reaction of equimolar amounts of α -ferrocenylcarbinols and heterocycles is carried out with vigorous stirring at room temperature. Two-phase system consists of an organic solvent (CH₂Cl₂) and aqueous solution (45%) of a tetrafluoroboric acid. Under these conditions reactions proceed predominantly at the organic inorganic interface. Methylene dichloride contains the

hydrophobic ferrocene compounds (initial and/or reaction product), and the aqueous phase contains acid. The polar hydroxy group of the organometallic carbinol is exposed to the aqueous phase and is thus available for protonation and formation under mild conditions of thermodynamically stable ferrocenylcarbocation, while the other part of ferrocene compound remains in the organic phase and is not subjected to protonation and oxidation. Therefore, the efficient interaction of the ferrocenyl carbocation with the corresponding nucleophilic reagent may occur, and other reactions (rearrangement, dimerisation, polymerisation, formation of ethers, etc.) are practically excluded.



Scheme 1. Ferrocenylalkylation of pyrrolidine-2-thione **2**.






Figure 1. General view of molecule of 1-(ferrocenyl(phenyl)methyl)pyrrolidine-2-thione **5f** presented in anisotropic displacement ellipsoids at 50% probability. Selected mean bond length and angles (Å and °): C5-C6 1.515(2), C5-C16 1.516(3), N1-C5 1.472(3), N1-C1 1.340(4), S1-C4 1.661(3), C3-C4 1.504(3), C6-C5-N1 110.48(18), N1-C4-S1 126.5(2).



Scheme 2. Ferrocenylalkylation of 2-mercaptothiazoline **3**.

It is found that all reactions proceed regioselectively at the heterocyclic nitrogen atom. Ferrocenylalkylation reaction in acidic media using ferrocenylcarbinols as alkylating agents started with formation of thermodynamically stable α -ferrocenium carbocation, which is relatively hard Lewis acid, efficiently react with somewhat harder basic center, in our case, with the nitrogen atom. Furthermore in our previous paper¹¹ quantum chemical calculations showed that N-isomers are more thermodynamically stable than the corresponding S-isomers. Structures of the reaction products (**5 a-d,f**, **6 a-c,e,f**) (Scheme 1,2) were established by ¹H–¹³C heteronuclear correlation experiments. Thus, HMBC NMR spectra of compounds exhibit characteristic correlations of the bridging alkyl group protons of the ferrocenylalkyl moieties with the C atoms of the C=S group (at about δ 180) and with the C(5) atoms of heterocycles. And, vice versa, there is correlation between C(5)H and linkage carbon atom. This is evidence in support of the substitution at the heterocyclic rings nitrogen.



Scheme 3. Ferrocenylalkylation of imidazolidin-2-thione **4**.

Ferrocenylalkylation of imidazole under the acid catalysis conditions in a two-phase aqueous-organic medium is impossible because of its high basicity, as a result of which the protonated imidazole salt is the single product of the reaction. Consequently, a method was developed for obtaining ferrocenylalkyl imidazoles

based on the interaction of ferrocene alcohols with carbonyl- or thionyl-diimidazoles.²¹ In contrast to imidazole and benzimidazole mercaptoimidazole and mercaptobenzimidazole are less basic so its ferrocenylalkylation possible under acid catalysis. In our early works ferrocenylalkylation was carried out in acetone using CF_3COOH as a catalyst,²² in our work we carried out the alkylation in a two-phase system.¹¹ Structures of the reaction products (**7 a-c,e,f**) (Scheme 3) were established by ^1H - ^{13}C heteronuclear correlation experiments, moreover structures of the two compounds were established by the X-ray diffraction method. X-ray crystallographic studies of **7a** and **7f** (Figures 2 and 3) show the typical for ferrocene derivatives bond lengths and angles. Apparently, the replacement of one hydrogen atoms bonded to tertiary carbon atom by *i*-Pr or Ph group lead to elongation of the distance between substituted thione group with ferrocenyl fragment. In crystal of **7a** the presence of NH group lead to formation of centrosymmetric dimers assembled via N-H...S bonds (Figure S8). In crystal packing of **7d** due to *i*-Pr group molecules are assembled to infinite chains along to *a* side of unit cell (Figure S9).




Figure 2. General view of molecule **7e** presented in anisotropic displacement ellipsoids at 50% probability. Selected mean bond length and angles (Å and °): C1-C2 1.508(12), C1-C12 1.534(11), N1-C1 1.464(10), N1-C15 1.344(10), 1.358(10), C15-S1 1.675(7), C2-C1-C12 113.3(6), N1-C15-S1 128.1(6), N1-C15-N2 108.6(6).




Figure 3. General view of molecule **7a** presented in anisotropic displacement ellipsoids at 50% probability. Selected bond length and angles (Å and °): C1-C11 1.488(3), C11-N1 1.460(3), N1-C14 1.350(3), C14-N2 1.335(3), C14-S1 1.683(2), C1-C11-N1 112.21(19), N1-C14-S1 125.51(19), N1-C14-N2 109.0(2)

Conclusions

Ferrocene containing derivatives of 2-mercaptopyridine **5 a-d,f**, pyrrolidine-2-thione **6 a-c,e,f** and imidazolidin-2-thione **7 a-c,e,f** were prepared via the reaction of the α -(hydroxy)alkyl ferrocenes with corresponding heterocycles in acidic media. Under these conditions, the alkylation takes place on the nitrogen of heterocycles and not by sulfur moiety.

Experimental Section

General. Solvents were dried following the standard procedures and distilled under argon prior to use. EI mass spectra were taken on a FINNIGAN POLARIS Q spectrometer at 70 eV and the temperature of the ion chamber 250 °C. ^1H and ^{13}C NMR spectra were obtained on a Bruker Avance 400 spectrometer (at 400 and 100 MHz, respectively) in CDCl_3 at 30 °C. The chemical shifts are given in the δ scale relative to the residual solvent signal. All signals in the NMR spectra were attributed using gradient HSQC and HMBC heteronuclear correlation techniques. Melting points were determined with a Stuart SMP30 apparatus (Bibby Scientific). Elemental analysis data were obtained in the Laboratory of microanalysis of A.N. Nesmeyanov Institute of Organoelement Compounds (INEOS RAS). Commercially available pyrrolidine-2-thione (**2**) 2-mercaptopyridine (**3**), and imidazolidin-2-thione (**4**) (Acros Organics) were used as purchased.

Ferrocenylmethanol (**1a**) was synthesized from trimethylferrocenylmethylammonium iodide by the known procedure.²³ Ferrocenyl carbinols (**1b–e**) were synthesized from ferrocene by the Friedel–Crafts acylation with the corresponding acid chlorides and subsequent reduction with lithium aluminum hydride in diethyl ether or THF.²⁴

General Procedure. To a mixture of 1.0 mmol of ferrocenylcarbinol and 1.0 mmol of the corresponding heterocycle in 1.0 ml of methylene dichloride, 0.18 ml of 45 % aqueous solution of fluoroboric acid was added under vigorous stirring. The agitation was continued for 5 min then Et₂O (15 ml), the same amount of cold water, and 5-10 mg of ascorbic acid were added to the reaction flask. After vigorous shaking of the mixture the organic solution was separated, washed with cold water (3×15 ml), the solvent was removed and the residue was dried over CaCl₂. All types of products (pyrrolidine as well as imidazolidine and thiazolidine derivatives) were equally purified, namely by column chromatography (silica, eluent hexane EtOAc 3:1), and solids obtained after chromatography were crystalized from ethanol.

1-(1-Ferrocenylmethyl)pyrrolidine-2-thione (5a). (85%); orange powder; mp 104.8 – 105.6°C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 2.02 (m, 2H, CH₂), 2.61 (m, 2H, CH₂), 3.90 (m, 2H, CH₂), 4.12 (s, 2H, Fc), 4.14 (s, 2H, CH₂), 4.13 (s, 5H, Fc), 4.25 (s, 2H, Fc). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 19.8 (CH₂), 45.2 (CH₂), 49.3 (CH₂), 52.1 (CH), 66.0 (C₅H₄), 67.6 (C₅H₄), 68.8 (C₅H₄), 68.9 (C₅H₄), 69.1 (C₅H₅), 86.9 (*ipso*-C₅H₄), 200.1 (C=S). Calc. for C₁₅H₁₇FeNS: C, 61.22; H, 5.74; N, 4.69; Fe, 18.67; S, 10.72. Found: C, 60.21; H, 5.73; Fe, 18.66; N, 4.68; S, 10.72. EI/MS, *m/z* (RI%): 299 [M]⁺ (46).

1-(1-Ferrocenylethyl)pyrrolidine-2-thione (5b). (75%); yellow powder, mp 88.1°C. EI/MS, *m/z* (RI%): 313 [M]⁺ (69). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.56 (d, 3H, *J* 7.0, CH₃), 1.88 (m, 2H, CH₂), 2.99 (m, 2H, CH₂), 3.23 (m, 1H, CH), 3.46 (m, H, CH), 4.11 (s, 1H, Fc), 4.17 (s, 2H, Fc), 4.21 (s, 5H, Fc), 4.30 (s, 1H, Fc), 6.08 (q, 1H, *J* 7.1, CH). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 15.6 (CH₃), 19.4 (CH₂), 45.2 (CH₂), 49.2 (CH₂), 51.5 (CH), 66.0 (C₅H₄), 67.5 (C₅H₄), 68.6 (C₅H₄), 68.8 (C₅H₄), 68.9 (C₅H₅), 86.7 (*ipso*-C₅H₄), 199.2 (C=S). Calc. for C₁₆H₁₉FeNS: C, 61.35; H, 6.11; Fe, 17.83; N, 4.47; S, 10.24. Found: C, 61.33; H, 6.12; Fe, 17.82; N, 4.48.

1-(1-Ferrocenylpropyl)pyrrolidine-2-thione (5c). (80%); yellow oil. EI/MS, *m/z* (RI%): 327 [M]⁺ (68). ¹H NMR (400 MHz, CDCl₃) δ (ppm): ¹H NMR (500 MHz, CDCl₃) δ (ppm) 0.99 (t, *J* 7.4 Hz, 3H, CH₃), 1.85 (m, 1H), 1.94 (m, 1H), 2.19 (dq, *J* 14.9, 7.5, 4.0 Hz, 1H), 3.00 (m, 1H), 3.25 (ddd, *J* 11.1, 8.5, 6.2 Hz, 1H), 3.41 (ddd, *J* 11.1, 8.4, 6.1 Hz, 1H), 4.12 (s, 2H, Fc), 4.15 (s, 1H, Fc), 4.18 (s, 5H, Fc), 4.31 (d, *J* 1.5 Hz, 1H), 6.01 (dd, *J* 11.6, 3.9 Hz, 1H, CH). ¹³C NMR (126 MHz, CDCl₃) δ (ppm): 10.94 (CH₃), 19.62 (CH₂), 24.00 (CH₂), 45.20 (CH₂), 48.62 (CH₂), 56.66 (CH), 66.08 (C₅H₄), 67.29 (C₅H₄), 68.21 (C₅H₄), 68.52 (C₅H₄), 69.01 (C₅H₅), 86.72 (*ipso*-C₅H₄), 200.99 (C=S). Calc. for C₁₇H₂₁FeNS: C, 62.39; H, 6.47; Fe, 17.06; N, 4.28; S, 9.80. Found: C, 62.37; H, 6.51; N, 4.29; Fe, 17.00.

1-(1-Ferrocenylbutyl)pyrrolidine-2-thione (5d). (77%); brown oil. EI/MS, *m/z* (RI%): 341 [M]⁺ (67). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.08 (t, 3H, *J* 7.3, CH₃), 1.41 (m, 2H, CH₂), 1.99 (m, 2H, CH₂), 3.03 (m, 2H, CH₂), 3.27 (m, 2H, CH₂), 3.45 (m, 2H, CH₂, Het), 4.15 (s, 2H, 2CH, C₅H₄), 4.18 (s, H, CH, C₅H₄), 4.21 (s, 5H, C₅H₅), 4.36 (s, 1H, CH, C₅H₄), 6.13 (m, 1H, CH). ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 11.1 (CH₃), 14.2 (CH₂), 19.4 (CH₂), 27.5 (CH₂), 33.2 (CH₂), 51.0 (CH₂), 56.4 (CH), 66.1 (C₅H₄), 67.5 (C₅H₄), 68.3 (C₅H₄), 68.8 (C₅H₄), 69.1 (C₅H₅), 86.6 (*ipso*-C₅H₄), 196.0 (C=S). Calc. for C₁₈H₂₃FeNS: C, 63.35; H, 6.79; N, 4.10; Fe, 16.36; S, 9.39. Found: C, 63.32; H, 6.74; N, 4.12; Fe, 16.33.

1-(Ferrocenyl(phenyl)methyl)pyrrolidine-2-thione (5f). (72%); orange powder, mp 131.5 – 132.3°C. EI/MS, *m/z* (RI%): 375 [M]⁺ (27). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.98 (m, 2H, CH₂), 3.08 (m, 2H, CH₂), 3.45 (m, 1H, CH), 3.70 (m, 1H, CH), 4.18 (s, 5H, C₅H₅), 4.22 (s, 1H, CH, C₅H₄), 4.26 (m, 4H, CH, C₅H₄ + CH), 7.37 (m, 5H, C₆H₅). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 20.1 (CH₂), 44.9 (CH₂), 51.1 (CH₂), 59.5 (CH), 67.9 (C₅H₄), 68.2 (C₅H₄), 68.5

(C₅H₄), 69.3 (C₅H₅), 85.3 (*ipso*-C₅H₄), 127.93 (C₆H₅), 128.40 (C₆H₅), 128.45 (C₆H₅), 138.1 (*ipso*-C₆H₅), 200.7 (C=S). Calc. for C₂₁H₂₁FeNS: C, 67.21; H, 5.64; N, 3.73; Fe, 14.88. S, 8.54. Found: C 67.23; H 4.65; N 3.75; Fe 14.80.

3-(1-Ferrocenylmethyl)thiazolidine-2-thione (6a). (57%); orange powder, mp 94.0 – 95.2°C. EI/MS, *m/z* (RI%): 317 [M]⁺ (84). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 3.09 (m, 2H, CH₂), 3.59 (m, 1H, CH), 3.79 (m, 1H, CH), 4.17 (m, 3H, C₅H₄), 4.20 (s, 5H, Fc), 4.36 (s, 1H, Fc), 6.09 (s, 2H, CH₂). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 33.2 (CH₂), 51.0 (CH₂), 56.4 (CH₂), 66.1 (C₅H₄), 67.5 (C₅H₄), 68.3 (C₅H₄), 68.8 (C₅H₄), 69.1 (C₅H₄), 86.5 (*ipso*-C₅H₄), 195.9 (C=S). Calc. for C₁₄H₁₅FeNS₂: C, 53.00; H, 4.77; N, 4.42; Fe, 17.60; S, 20.21. Found: C, 53.04; H, 4.81; Fe, 17.63.

3-(1-Ferrocenylethyl)thiazolidine-2-thione (6b). (61%); yellow powder, mp 123.3-124°C. EI/MS, *m/z* (RI%): 331 [M]⁺ (73). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.61 (d, 3H, *J* 7.0, CH₃), 3.11 (m, 2H, CH₂), 3.61 (m, 1H, CH), 3.83 (m, 1H, CH), 4.23 (m, 8H, Fc), 4.36 (s, 1H, Fc), 6.11 (m, 1H, CH). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 15.4 (CH₃), 29.1 (CH₂), 35.2 (CH₂), 51.5 (CH), 66.3 (C₅H₄), 67.6 (C₅H₄), 68.3 (C₅H₄), 68.8 (C₅H₄), 68.9 (C₅H₅), 86.4 (*ipso*-C₅H₄), 195.2 (C=S). Anal.: C, 54.37; H, 5.18; N, 4.21; Fe, 16.90. C₁₅H₁₇FeNS₂: C, 54.38; H, 5.17; N, 4.23; Fe, 16.86.

3-(1-Ferrocenylpropyl)thiazolidine-2-thione (6c). (47%); orange oil. EI/MS, *m/z* (RI%): 345 [M]⁺ (45). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 1.06 (t, 3H, *J* 7.4, CH₃), 1.86 (m, 1H, CH), 2.23 (m, 1H, CH), 3.11 (m, 1H, CH), 3.19 (m, 1H, CH), 3.61 (m, 1H, CH), 3.80 (m, 1H, CH), 4.17 (s, 3H, C₅H₄), 4.21 (s, 5H, C₅H₅), 4.36 (s, 1H, C₅H₄), 6.02 (m, 1H, CH). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 16.2 (CH₃), 27.5 (CH₂), 33.2 (CH₂), 51.0 (CH₂), 57.5 (CH), 66.2 (C₅H₄), 67.3 (C₅H₄), 68.2 (C₅H₄), 68.7 (C₅H₄), 69.2 (C₅H₄), 86.7 (*ipso*-C₅H₄), 195.8 (C=S). Calc. for C₁₆H₁₉FeNS₂: C, 55.65; H, 5.55; N, 4.06; Fe, 16.17; S, 18.57. Found: C, 55.68; H, 5.57; N, 4.05; Fe, 16.22.

3-(1-Ferrocenyl-2-methylpropyl)thiazolidine-2-thione (6e). (65%); yellow powder, mp 127 – 128°C. EI/MS, *m/z* (RI%): 359 [M]⁺ (85). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 0.97 (d, 3H, *J* 6.6, CH₃), 1.11 (d, 3H, *J* 6.6, CH₃), 3.23 (m, 2H, CH₂), 3.95 (m, 2H, CH₂), 4.10 (s, 1H, Fc), 4.19 (s, 8H, Fc), 5.61 (d, 1H, CH). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 20.1 (CH₃), 21.2 (CH₃), 27.6 (Het), 31.8 (Het), 52.4 (CH), 62.7 (C₅H₄), 66.3 (C₅H₄), 66.8 (C₅H₄), 68.5 (C₅H₄), 69.2 (C₅H₄), 87.2 (*ipso*-C₅H₄), 195.7 (C=S). Calc. for C₁₇H₂₁FeNS₂: C, 56.82; H, 5.89; N, 3.90; Fe, 15.54; S, 17.84. Found: C, 56.83; H, 5.88; N, 3.92; Fe, 15.55.

3-(1-Ferrocenyl(methyl)phenyl)thiazolidine-2(3H)-thione (6f). (69%); orange crystals, mp 141.1 – 143°C. EI/MS, *m/z* (RI%): 393 [M]⁺ (36). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 3.12 (m, 1H, CH), 3.18 (m, 1H, CH), 3.73 (m, 1H, CH), 4.04 (m, 1H, CH), 4.18 (s, 1H, Fc), 4.20 (s, 5H, Fc), 4.24 (s, 1H, Fc), 4.26 (s, 1H, Fc), 4.28 (s, 1H, Fc), 7.36 (m, 5H, Ph). ¹³C NMR (100 MHz, CDCl₃) δ (ppm): 53.1 (CH₂), 60.5 (CH), 67.9 (C₅H₄), 68.1 (C₅H₄), 68.6 (C₅H₄), 69.4 (C₅H₄), 69.4 (C₅H₅), 85.3 (*ipso*-C₅H₄), 128.1 (C₆H₅), 128.3 (C₆H₅), 128.6 (C₆H₅), 138.1 (*ipso*-C₆H₅), 196.1 (C=S). Calc. for C₂₀H₁₉FeNS₂: C, 61.07; H, 4.87; N, 3.56; Fe, 14.20; S, 17.84. Found: C, 61.10; H, 4.85; N, 3.52; Fe, 14.28.

4,5-Dihydro-1-(1-ferrocenylmethyl)-1H-imidazole-2-thiol (7a). (69%); orange crystals, mp 184°C. EI/MS, *m/z* (RI%): 300 [M]⁺ (32). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 3.48 (m, 4H), 4.13 (s, 2H, Fc), 4.18 (s, 5H, Fc), 4.26 (s, 2H, Fc), 4.54 (s, 2H, CH₂), 5.92 (s, 1H, NH). ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 41.2 (CH₂), 46.5 (CH₂), 47.8 (CH₂), 68.3 (C₅H₄), 68.4 (C₅H₄), 68.7 (C₅H₄), 69.5 (C₅H₅), 81.7 (*ipso*-C₅H₄), 182.4 (C=S). Calc. for C₁₄H₁₆FeN₂S: C, 56.01; H, 5.37; N, 9.33; Fe, 18.60; S, 10.68. Found: C, 56.00; H, 5.40; N, 9.35; Fe, 18.50.

4,5-Dihydro-1-(1-ferrocenylethyl)-1H-imidazole-2-thiol (7b). (72%); orange crystals, mp 160°C. EI/MS, *m/z* (RI%): 314 [M]⁺ (48). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 5.99 (s, 1H, NH), 5.72 (q, *J* 7.0, 1H, CH), 4.36 (s, 1H, Fc), 4.15 (m, 8H, Fc), 3.52 – 3.35 (m, 3H, CH₂+CH), 3.25 – 3.12 (m, 1H, CH₂), 1.52 (d, *J* 7.0, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 16.2 (CH₃), 41.4 (CH₂), 43.4 (CH₂), 50.5 (CH), 66.0 (C₅H₄), 67.4 (C₅H₄), 68.6 (C₅H₄), 68.7 (C₅H₄), 68.9 (C₅H₅), 87.4 (*ipso*-C₅H₄), 182.1 (C=S). Calc. for C₁₅H₁₈FeN₂S: C, 57.34; H, 5.77; N, 8.92; Fe, 17.77; S, 10.20. Found: C, 57.32; H, 5.80; N, 8.90; Fe, 17.80.

4,5-Dihydro-1-(1-ferrocenylpropyl)-1H-imidazole-2-thiol (7c). (66%); yellow oil. EI/MS, *m/z* (RI%): 328 [M]⁺ (48). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 5.99 (s, 1H, NH), 5.72 (q, *J* 7.0, 1H, CH), 4.36 (s, 1H, Fc), 4.15 (m, 8H, Fc), 3.52

– 3.35 (m, 3H, CH₂+CH), 3.25 – 3.12 (m, 1H, CH₂), 1.52 (d, *J* 7.0, 3H, CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 10.2 (CH₃), 16.3 (CH₂), 27.5 (CH₂), 41.2 (CH₂), 43.5 (CH₂), 52.5 (CH), 66.2 (C₅H₄), 67.3 (C₅H₄), 68.2 (C₅H₄), 68.7 (C₅H₄), 69.2 (C₅H₄), 86.7 (*ipso*-C₅H₄), 182.6 (C=S). Calc. for C₁₆H₂₀FeNS₂: C, 58.54; H, 6.14; N, 8.53; Fe, 17.01; S, 9.77. Found: C, 58.53; H, 6.10; N, 8.50; Fe, 16.96.

4,5-Dihydro-1-(1-ferrocenyl-2methylpropyl)-1H-imidazole-2-thiol (7e). (76%); orange crystals, mp 153°C. EI/MS, *m/z* (RI%): 342 [M]⁺ (51). ¹H NMR (400 MHz, CDCl₃) δ 0.97 (d, *J* 6.6, 3H, CH₃), 1.04 (d, *J* 6.6, 3H, CH₃), 1.93 (ddt, *J* 13.2, 10.4, 6.6, 1H, CH), 3.65 (m, 4H, 2CH₂), 4.09 (s, 2H, Fc), 4.14 (s, 2H, Fc), 4.18 (s, 5H, Fc), 5.21 (d, *J* 10.3, 1H, CH), 5.72 (s, 1H, NH). ¹³C NMR (101 MHz, CDCl₃) δ 20.3 (CH₃), 21.1 (CH₃), 27.6 (CH), 41.5 (CH₂), 43.4 (CH₂), 52.7 (CH), 66.4 (C₅H₄), 67.2 (C₅H₄), 68.6 (C₅H₄), 68.9 (C₅H₄), 69.5 (C₅H₄), 86.4 (*ipso*-C₅H₄), 182.5 (C=S). Calc. for C₁₇H₂₂FeNS₂: C, 59.65; H, 6.48; N, 8.18; Fe, 16.32; S, 9.37. Found: C, 59.58; H, 6.41; N, 8.50; Fe, 16.26.

4,5-Dihydro-1-(1-ferrocenyl(phenyl)methyl)-1H-imidazole-2-thiol (7f). (78%); yellow crystals, mp 149°C. EI/MS, *m/z* (RI%): 376 [M]⁺ (46). ¹H NMR (400 MHz, CDCl₃) δ 3.40 (1H, m, CH₂), 3.54 (2H, m, CH₂), 3.74 (1H, m, CH₂), 4.16 (2H, s, Fc), 4.23 (5H, s, Fc), 4.30 (1 H, s, Fc), 6.13 (1H, s, NH), 7.02 (1H, s, CH), 7.36 (5H, m, Ph), ¹³C NMR (101 MHz, CDCl₃) δ 41.5 (CH₂), 45.1 (CH₂), 58.7 (CH), 67.7 (C₅H₄), 68.1 (C₅H₄), 68.2 (C₅H₄), 69.2 (C₅H₄), 69.3 (C₅H₅), 86.2 (*ipso*-C₅H₄), 127.7 (C₆H₅), 128.3 (C₆H₅), 128.4 (C₆H₅), 138.9 (*ipso*-C₆H₅), 183.3 (C=S). Calc. for C₂₀H₂₀FeN₂S: C, 63.84; H, 5.36; N, 7.44; Fe, 14.84; S, 8.52. Found: C, 63.88; H, 5.32; N, 7.42; Fe, 14.80.

X-ray crystallography

Single-crystal X-ray diffraction experiments for **5f**, **7a** and **7e** were carried out at 100 K on a Bruker APEX II diffractometer. Crystal data and experimental parameters are summarized in Table S1. The structures were solved by direct methods and refined by full-matrix least-squares technique for non-hydrogen atoms in the anisotropic approximation. All H-atoms were placed in the geometrically calculated positions and included in the refinement using the riding model approximation with the $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ for the methylene and $U_{\text{iso}}(\text{H}) = 1.5 U_{\text{eq}}(\text{C})$ for methyl groups. All calculations were carried out on IBM PC using SHELXTL program.²⁵ Molecular graphics was produced by OLEX2 program.²⁶ All measurements were carried out in of Center for molecular composition studies of INEOS RAS.

Crystal data for **5f**, **7a** and **7e** were deposited in the Cambridge Crystallographic Data Centre (deposition numbers CCDC 1583214-1583216). These data are freely available from the Cambridge database upon request through the web page www.ccdc.cam.ac.uk/data_request/cif.

Acknowledgements

This work was financially supported by the Russian Science Foundation (Project No. 17-73-30036). E.Yu. Rogatkina is grateful for financial support Russian Foundation for Basic Research (Project No. 16-33-60163 mol_a_dk; synthesis of ferrocenylalkylated *N,S*-heterocycles).

Supplementary Material

¹H, ¹³C, and 2D NMR spectra of **5c**, general view of **5f**, **7a,e**, the dimers in crystal packing of **7a**, the chains in crystal packing of **7e**, main crystallographic data and refinement parameters for compounds **5f**, **7a,e** (figures S1-S9 and table S1).

References

1. Neuse, E. W. J. *Inorg. Organomet. Polymer. Mater.* **2005**, *15* (1), 3.
<https://doi.org/10.1007/s10904-004-2371-9>
2. Babin, V. N. ; Belousov, Yu A.; Borisov, V. I.; Gumenyuk, V. V. ; Nekrasov, Yu S.; Ostrovskaya, L. A.; Sviridova, I. K.; Sergeeva, N. S.; Simenel, A. A. and Snegur. L. V. *Russ. Chem. Bull.* **2014**, *63*, 2405.
<https://doi.org/10.1007/s11172-014-0756-7>
3. Larik, F. A. ; Saeed, A. ; Fattah, T. A. ; Muqadar, U. ; Channar, P. A. *Appl Organometal Chem.* **2017**, *31*, 1.
<https://doi.org/10.1002/aoc.3664>
4. Snegur, L.V.; Zykova, S.I.; Simenel, A.A.; Nekrasov, Y.S.; Starikova, Z.A.; Peregudova, S.M.; Ilyin, M.M.; Kachala, V.V.; Sviridova, I.K.; Sergeeva, N.S. *Russ. Chem. Bull.* **2013**, *62*, 2056.
<https://doi.org/10.1007/s11172-013-0298-4>
5. Snegur, L. V.; Nekrasov, Yu S.; Sergeeva, N. S.; Zhilina, Zh V.; Gumenyuk, V. V.; Starikova, Z. A.; Simenel, A. A.; Morozova, N. B.; Sviridova, I. K.; and Babin, V. N. *Appl. Organomet. Chem.* **2008**, *22*, 139.
<https://doi.org/10.1002/aoc.1362>
6. Jaouen, G.; Vessières, A.; Top, S. *Chem. Soc. Rev.* **2015**, *44*, 8802.
<https://doi.org/10.1039/C5CS00486A>
7. Rodionov, A.N.; Snegur, L.V.; Simenel, A.A.; Dobryakova, Y.V.; Markevich, V.A. *Russ. Chem. Bull.* **2017**, *66*, 136.
<https://doi.org/10.1007/s11172-017-1711-1>
8. Snegur, L.V.; Simenel, A.A.; Rodionov, A.N.; Boev, V.I. *Russ. Chem. Bull.* **2014**, *63*, 26.
<https://doi.org/10.1007/s11172-014-0390-4>
9. Osipova, E.Yu.; Rodionov, A.N.; Belousov, Yu.A.; Il'in, M.M.; Nikolaev, A.L.; Gopin, A.V.; Mazina, S.E.; and Simenel, A.A. *Russ.J. Org. Chem.* **2016**, *52* (1), 127.
<https://doi.org/10.1134/S1070428016010243>
10. Rodionov, A.N.; Gerasimova, M.D.; Osipova, E.Yu.; Korlyukov A.A.; Peregudov A.S.; Simenel A.A. *Monatsh. Chem.* **2017**, *148*, 925.
<https://doi.org/10.1007/s00706-016-1895-3>
11. Osipova, E. Yu.; Ivanova, A. S.; Rodionov, A. N.; Korlyukov, A. A.; Arkhipov, D. E.; Simenel, A. A. *Russ. Chem. Bull.* **2016**, *65*, 2868.
<https://doi.org/10.1007/s11172-016-1670-y>
12. Barnes, N.J. ; Barber, R.A. U.S. Patent 5 726 129, 1998.
<https://patentimages.storage.googleapis.com/78/75/70/edf99be8f320a7/US5726129.pdf>
13. Huang, Zh. ; Huang, M. ; Mi, Ch.; Wang, T. ; Chen, D. ; Teng, Y. *Int. J. Mol. Sci.* **2016**, *17*, 1330.
<https://doi.org/10.3390/ijms17081330>
14. Sharma P. Ch., Kumar R., Chaudhary M., Sharma A., Rajak H. *J. of Enzyme Inhib. Med. Chem.* **2013**, *28*, 1.
<https://doi.org/10.3109/14756366.2011.611943>
15. Kouge K., Koizumi T., Ishibashi N. and Okai H. *Agric. Biol. Chem.* **1987**, *51* (7), 1941.
<http://doi.org/10.1271/bbb1961.51.1941>
16. Kashyap, S.J.; Garg, V.K.; Sharma, P.K.; Kumar, N.; Dudhe, R.; Gupta J.K. *Med. Chem. Res.* **2012**, *21*, 2123.
<https://doi.org/10.1007/s00044-011-9685-2>
17. Eicher, T.; Hauptmann, S. *The Chemistry of Heterocycles*, second ed., WileyVCH: Weinheim, 2003, p149.
<https://doi.org/10.1002/352760183X>

18. Altintop, M.D.; Kaplancikli, Z.A.; Çiftçi, G.A.; Demirel R. *Eur. J. Med. Chem.* **2014**, *74*, 264.
<https://doi.org/10.1016/j.ejmech.2013.12.060>
19. Fendt, M.; Endres, T. *Neuroscience and Biobehavioral Rev.* **2008**, *32*, 1259.
<https://doi.org/10.1016/j.neubiorev.2008.05.010>
20. Liu, J.C.; Liang, Y.; He, H.W. *Chin. Chem. Lett.* **2013**, *24*, 233.
<https://doi.org/10.1016/j.ccllet.2013.01.036>
21. Simenel, A.A.; Kuzmenko, Yu V.; Morozova, E.A.; Ilyin, M.M.; Gúnko, I.F.; Snegur, L.V. *J. Organomet. Chem.*, **2003** 688, 138.
<https://doi.org/10.1016/j.jorganchem.2003.08.039>
22. Rodionov, A.N.; Zherebker, K.Ya.; Snegur, L.V.; Korlyukov, A.A.; Arhipov, D.E.; Peregudov, A.S.; Ilyin, M.M.; Ilyin Jr., M.M.; Nikitin, O.M.; Morozova, N.B.; Simenel, A.A. *J. Organomet. Chem.* **2015**, *783*, 83.
<https://doi.org/10.1016/j.jorganchem.2015.01.031>
23. Lindsay, J.K.; Hauser, C.R. *J. Org. Chem.* **1957**, *22*, 355.
<https://doi.org/10.1021/jo01355a001>
24. Arimoto, F.S.; Haven, A.S. *J. Am. Chem. Soc.* **1955**, *77*, 6295.
<https://doi.org/10.1021/ja01628a068>
25. Sheldrick, G.M. *Acta Crystallogr.* **2008**, *A64*, 112.
<https://doi.org/10.1107/S0108767307043930>
26. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. *J. Appl. Crystallogr.* **2009**, *42*, 339.
<https://doi.org/10.1107/S0021889808042726>